Market Cap 965.55M
Revenue (ttm) 55.25M
Net Income (ttm) -334.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -605.12%
Debt to Equity Ratio -0.51
Volume 505,300
Avg Vol 1,184,666
Day's Range N/A - N/A
Shares Out 70.94M
Stochastic %K 72%
Beta 0.43
Analysts Strong Sell
Price Target $21.38

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
Journeybronn
Journeybronn Oct. 25 at 4:50 PM
$PHAT what’s this going to do for us on Monday? https://finance.yahoo.com/news/phathom-pharmaceuticals-announces-publication-data-135900842.html
1 · Reply
Wirralboy
Wirralboy Oct. 25 at 2:57 PM
$PHAT The consensus average price target for Phathom Pharmaceuticals (PHAT) is approximately $21.38 to $23.50, with a range of $12.00 to $29.00 from different analysts. This represents an average upside potential of around 59% from its current trading price, based on recommendations from multiple analysts. Price target and analyst ratings Average Price Target: ~$21.38 to $23.50 Price Target Range: $12.00 (low) to $29.00 (high) Analyst Consensus: Strong Buy Upside Potential: Approximately 59%
0 · Reply
Wirralboy
Wirralboy Oct. 25 at 2:46 PM
$PHAT just released Phathom Pharmaceuticals announced positive results related to its medication, VOQUEZNA (vonoprazan), for treating nighttime gastroesophageal reflux disease (GERD) symptoms, as reported in the American Journal of Gastroenterology. In the Phase 3 pHalcon-NERD-301 trial, VOQUEZNA provided rapid and sustained relief from nighttime GERD symptoms, with significant improvements in heartburn-free nights observed after the first dose and maintained over 24 weeks. The trial findings revealed that VOQUEZNA led to clinically meaningful reductions in nocturnal symptom severity and enhanced sleep quality for patients with Non-Erosive Reflux Disease (NERD). The drug was well tolerated with manageable side effects, adding to the evidence of its effectiveness in a patient population that often struggles with existing therapies. The publication aims to highlight VOQUEZNA's potential role in addressing an underrecognized aspect of GERD and improving patient quality of life.
0 · Reply
RonIsWrong
RonIsWrong Oct. 24 at 11:04 PM
$PHAT holding new levels
0 · Reply
Morrito23
Morrito23 Oct. 24 at 6:51 PM
$PHAT This has to be the lowest volume I’ve seen in a while!
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 24 at 6:13 PM
$PHAT Current Stock Price: $13.41 Contracts to trade: $10 PHAT Nov 21 2025 Call Entry: $3.60 Exit: $6.10 ROI: 70% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
stocksUP59
stocksUP59 Oct. 24 at 5:46 PM
2 · Reply
fgggggggg
fgggggggg Oct. 24 at 2:46 PM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 12:29 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PHAT Current Share Price: $13.66 Contracts: $PHAT January 15, 2027 $18 Calls Scale in: $4.50- $5.50 Scale out: $7.00-$9.00 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
theDIOyears
theDIOyears Oct. 23 at 11:15 PM
$XTNT no major selling. Boring but hopeful day. A new company, a profitable business, a vertically integrated undervalued stock. The new base? $PHAT $BIIB $LGCY
0 · Reply
Latest News on PHAT
Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX


Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Announces Leadership Succession


Phathom Pharma Is A Buy Before July PDUFA

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA


Journeybronn
Journeybronn Oct. 25 at 4:50 PM
$PHAT what’s this going to do for us on Monday? https://finance.yahoo.com/news/phathom-pharmaceuticals-announces-publication-data-135900842.html
1 · Reply
Wirralboy
Wirralboy Oct. 25 at 2:57 PM
$PHAT The consensus average price target for Phathom Pharmaceuticals (PHAT) is approximately $21.38 to $23.50, with a range of $12.00 to $29.00 from different analysts. This represents an average upside potential of around 59% from its current trading price, based on recommendations from multiple analysts. Price target and analyst ratings Average Price Target: ~$21.38 to $23.50 Price Target Range: $12.00 (low) to $29.00 (high) Analyst Consensus: Strong Buy Upside Potential: Approximately 59%
0 · Reply
Wirralboy
Wirralboy Oct. 25 at 2:46 PM
$PHAT just released Phathom Pharmaceuticals announced positive results related to its medication, VOQUEZNA (vonoprazan), for treating nighttime gastroesophageal reflux disease (GERD) symptoms, as reported in the American Journal of Gastroenterology. In the Phase 3 pHalcon-NERD-301 trial, VOQUEZNA provided rapid and sustained relief from nighttime GERD symptoms, with significant improvements in heartburn-free nights observed after the first dose and maintained over 24 weeks. The trial findings revealed that VOQUEZNA led to clinically meaningful reductions in nocturnal symptom severity and enhanced sleep quality for patients with Non-Erosive Reflux Disease (NERD). The drug was well tolerated with manageable side effects, adding to the evidence of its effectiveness in a patient population that often struggles with existing therapies. The publication aims to highlight VOQUEZNA's potential role in addressing an underrecognized aspect of GERD and improving patient quality of life.
0 · Reply
RonIsWrong
RonIsWrong Oct. 24 at 11:04 PM
$PHAT holding new levels
0 · Reply
Morrito23
Morrito23 Oct. 24 at 6:51 PM
$PHAT This has to be the lowest volume I’ve seen in a while!
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 24 at 6:13 PM
$PHAT Current Stock Price: $13.41 Contracts to trade: $10 PHAT Nov 21 2025 Call Entry: $3.60 Exit: $6.10 ROI: 70% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
stocksUP59
stocksUP59 Oct. 24 at 5:46 PM
2 · Reply
fgggggggg
fgggggggg Oct. 24 at 2:46 PM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 12:29 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PHAT Current Share Price: $13.66 Contracts: $PHAT January 15, 2027 $18 Calls Scale in: $4.50- $5.50 Scale out: $7.00-$9.00 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
theDIOyears
theDIOyears Oct. 23 at 11:15 PM
$XTNT no major selling. Boring but hopeful day. A new company, a profitable business, a vertically integrated undervalued stock. The new base? $PHAT $BIIB $LGCY
0 · Reply
Snatchman
Snatchman Oct. 23 at 7:23 PM
$PHAT so, do the shorts just hang around and wait for the early report next week? Historically, early reports have skewed to be more positive... I'm confused at a shorts thought process
1 · Reply
Snatchman
Snatchman Oct. 23 at 7:02 PM
0 · Reply
Snatchman
Snatchman Oct. 22 at 5:57 PM
0 · Reply
Hendo111
Hendo111 Oct. 22 at 4:11 PM
0 · Reply
Walleyeslayer
Walleyeslayer Oct. 22 at 2:41 PM
$PHAT volume of 90,000 shares. Low volume move down. Any large add shoots it back up. 👀
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Oct. 22 at 12:10 PM
$PHAT I’ll bet this attracts some short squeeze action with its short percent
0 · Reply
Snatchman
Snatchman Oct. 21 at 7:55 PM
$PHAT just feels like something is up. Something besides the fact that patients LOVE the drug
1 · Reply
Walleyeslayer
Walleyeslayer Oct. 21 at 6:19 PM
0 · Reply
Hendo111
Hendo111 Oct. 21 at 3:59 PM
0 · Reply
Snatchman
Snatchman Oct. 21 at 2:28 PM
0 · Reply
bullmarket4
bullmarket4 Oct. 21 at 12:33 PM
0 · Reply
dgbio
dgbio Oct. 21 at 12:03 PM
$PHAT 'Researchers at the University of Texas and MIT have discovered hidden information contained in when exactly companies chose to schedule their quarterly earnings releases. If a company schedules its earnings much earlier than normal, then earnings are often better than expected and share price gains typically follow.' https://www.forbes.com/sites/simonmoore/2019/01/30/the-hidden-signal-in-delayed-earnings-announcements/?utm_source=perplexity
0 · Reply